Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
Novo Nordisk’s blockbuster GLP-1 analog Wegovy (semaglutide) can maintain meaningful weight loss for up to four years and improve cardiovascular health regardless of the amount of weight lost, ...
LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's (NOVOb.CO) , opens new tab Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the ...
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
LONDON - Patients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10 per cent weight loss after four years, potentially boosting the drugmaker’s case to insurers and ...
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond strongly to Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy ...
LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo ...
FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top ...
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are ...